The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
QuANTUM-First: A post hoc analysis of the impact of allo-HSCT and quizartinib in newly diagnosed FLT3-ITD-positive AML
Quizartinib, a selective FLT3 inhibitor, has been approved by the US Food and Drug Administration for newly diagnosed FLT3-ITD AML in combination with chemotherapy, based on the data from the QuANTUM-First trial (NCT02668653). A post hoc analysis from the QuANTUM-First phase III trial assessing the impact of allo-HSCT and quizartinib in patients with FLT3-ITD AML in CR1 and CRc1 was published by Schlenk et al. in Haematologica. A total of 144 and 128 patients in the quizartinib and placebo groups, respectively, from the ITT population (N = 539) underwent allo-HSCT. Outcomes included OS in CR1 and CRc1, RFS, and safety.
|
Key learnings |
In patients who achieved CR1 by the end of induction, quizartinib and allo-HSCT were predictors of longer OS (HR, 0.553; p = 0.0015 and HR, 0.527; p = 0.0023, respectively). |
Quizartinib (HR, 0.645; p = 0.0068) and allo-HSCT (HR, 0.557; p = 0.0012) provided an OS advantage for patients who achieved CRc1 by the end of induction. RFS was longer among patients achieving CR/CRc, irrespective of undergoing allo-HSCT or not (HR, 0.607 and HR, 0.682, respectively). |
Among patients undergoing allo-HSCT, aGvHD occurred in 45.1% vs 38.5% and cGvHD in 29.4% vs 19.8% of patients in the quizartinib and placebo groups, respectively. Grade 3–4 aGvHD rates were higher in the quizartinib group compared with placebo (16.7% vs 6.6%). No new safety signals were identified. |
Data from this QuANTUM-First post hoc analysis supports quizartinib and allo-HSCT as an effective and well-tolerated treatment strategy for newly diagnosed FLT3-ITD AML. The small sample size and variation in allo-HSCT eligibility based on the investigator’s decision should be considered when interpreting the results. |
Abbreviations: aGVHD, acute graft-versus-host disease; allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; CI, confidence interval; CR1, first complete remission; CRc1, first composite complete remission; FLT3-ITD, FMS-like tyrosine kinase 3 internal tandem duplication; HR, hazard ratio; ITT, intent-to-treat; OS, overall survival; RFS, relapse-free survival.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
